Benitec Biopharma (BNTC)
(Delayed Data from NSDQ)
$8.15 USD
-0.01 (-0.12%)
Updated Sep 13, 2024 03:59 PM ET
After-Market: $8.13 -0.02 (-0.25%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.15 USD
-0.01 (-0.12%)
Updated Sep 13, 2024 03:59 PM ET
After-Market: $8.13 -0.02 (-0.25%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Zacks News
Axovant, Benitec Gain on Licensing Deal for Gene Therapy
by Zacks Equity Research
Axovant Sciences' (AXON) shares gain, following the news of a licensing deal for oculopharyngeal muscular dystrophy candidate with Benitec Biopharma.
Bioblast (ORPN) SCA3 Drug Favorable in Phase IIa Study
by Zacks Equity Research
Bioblast (ORPN) announced results from a phase IIa study on trehalose for the treatment of patients with spinocerebellar ataxia type 3.
Benitec Stock Up on Orphan Drug Status for BB-301 in EU
by Zacks Equity Research
Benitec (BNTC) announced that its proposed candidate, BB-301, received Orphan Drug Designation in the EU for the treatment of ocularpharyngeal muscular dystrophy.